Synthetic graphene–copper nanocomposites interact with the hACE-2 enzyme and inhibit its biochemical activity-Reference-Cited by-同舟云学术

Synthetic graphene–copper nanocomposites interact with the hACE-2 enzyme and inhibit its biochemical activity

Published:2024 Issue:1 Volume:6 Page:188-196
ISSN:2516-0230
Container-title:Nanoscale Advances
language:en
Short-container-title:Nanoscale Adv.

Author:

Sulthana Shoukath¹,Bhatti Abeera²,Mathew Elza²^ORCID,Quazi Sohel H.¹³,Gaudreault Natasha N.²,DeLong Robert⁴^ORCID,Aryal Santosh¹^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences and Health Outcomes, The Ben and Maytee Fisch College of Pharmacy, University of Texas at Tyler, Tyler, TX 75799, USA

2. Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, 66506, USA

3. Department of Biology, Division of Natural and Computational Sciences, Texas College, Tyler, TX 75702, USA

4. Landmark Bio, Innovation Development Laboratory, Watertown, MA 02472, USA

Abstract

Graphene–Cu and copper oxide nanocomposites showed an enhanced inhibitory effect against the hACE-2 enzyme, which is one of the passages for COVID infection.

Funder

Division of Chemical, Bioengineering, Environmental, and Transport Systems

National Science Foundation

Publisher

Royal Society of Chemistry (RSC)

Subject

General Engineering,General Materials Science,General Chemistry,Atomic and Molecular Physics, and Optics,Bioengineering

Link

http://pubs.rsc.org/en/content/articlepdf/2024/NA/D3NA00468F

Reference45 articles.

1. Research, C. for D. E. and FDA Approves Liposome-Encapsulated Combination of Daunorubicin-Cytarabine for Adults with Some Types of Poor Prognosis AML , FDA , 2019

2. Drugs@FDA: FDA-Approved Drugs , https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050718 , accessed 2022-06-15

3. Dexrazoxane (Totect™): FDA Review and Approval for the Treatment of Accidental Extravasation Following Intravenous Anthracycline Chemotherapy

4. Albumin-bound paclitaxel: a next-generation taxane

5. Natural killer cell membrane infused biomimetic liposomes for targeted tumor therapy